Home » Authors » Brady Huggett

Articles by Brady Huggett

LSE Rule Change Meant To Spark More Foreign Listings In London

May 30, 2003

By Brady Huggett

Awaiting Cialis Decision, ICOS Files $150M Shelf Registration

May 29, 2003

By Brady Huggett

Awaiting Cialis Decision, ICOS Files $150M Shelf Registration

May 29, 2003

By Brady Huggett

Peninsula In-Licenses Late-Stage Antibiotic From Japanese Firm

May 28, 2003

By Brady Huggett

Peninsula In-Licenses Late-Stage Antibiotic From Japanese Firm

May 28, 2003

By Brady Huggett

BioMS Plans Pivotal Trial Talks On MBP8289 Phase II MS Results

May 27, 2003

By Brady Huggett

BioMS Plans Pivotal Trial Talks On MBP8289 Phase II MS Results

May 27, 2003

By Brady Huggett

Maxygen Signs Interferon Deal With Roche Worth Up To $230M

May 23, 2003

By Brady Huggett

Maxygen Inc. signed a deal with F. Hoffmann-La Roche Ltd. focused on Maxygen's interferon alpha and beta variants portfolio. At this point, Roche has rights to candidates for hepatitis B and C, but if it takes its option on other indications, the deal's value could blossom to more than $230 million. (BioWorld Today)

Maxygen Signs Interferon Deal With Roche Worth Up To $230M

May 23, 2003

By Brady Huggett

Maxygen Inc. signed a deal with F. Hoffmann-La Roche Ltd. focused on Maxygen's interferon alpha and beta variants portfolio. At this point, Roche has rights to candidates for hepatitis B and C, but if it takes its option on other indications, the deal's value could blossom to more than $230 million. (BioWorld Today)

Connetics Seeking $75M Through Notes Sale As It Nears Profitability

May 22, 2003

By Brady Huggett

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...